Vetter, a globally-operating Contract Development and Manufacturing Organization (CDMO), has released its second annual sustainability report. The report includes Scope 3 emissions for the first time and shows Vetter's CO2 balance according to the international Greenhouse Gas Protocol requirements. The company aims to reduce total emissions globally by ten percent by 2029 compared to the base ye..
Vyriad, Inc. has announced an expansion of a Phase 1 trial at Mayo Clinic for patients with peripheral T-cell lymphoma (PTCL) using Voyager-V1 therapy after encouraging initial results. Regeneron Pharmaceuticals is co-developing the investigational therapy to treat patients with recurrent or treatment resistant cancers by dissolving cancer cells and stimulating the patient's immune system to pre..
Employee engagement continues to decline, with half of U.S. respondents stating they are not engaged at work and 17% actively disengaged, according to a Gallup study. This marks the second consecutive year of declining self-reported levels of employee engagement. The data also shows that many employees are ready to find new employment opportunities, with 71% stating now is a good time to do so a..
Biopharma companies are increasingly becoming targets of ransomware attacks, with the number of breaches rising during the COVID-19 pandemic. Japanese company Eisai recently announced that it was hit by a ransomware attack, joining other pharmaceutical companies like Sun Pharmaceuticals, Novartis and AstraZeneca. According to Constella Intelligence, for the top 20 pharma companies, the total num..
Merck's efinopegdutide has received FDA Fast Track designation for the treatment of non-alcoholic steatohepatitis (NASH), and Merck has released Phase IIa study results comparing efinopegdutide to Novo Nordisk's semaglutide. The new NAFLD data will be presented at the upcoming European Association for the Study of the Liver annual congress, and Merck plans to use both this data and the Fast Trac..
Biogen has partnered with NeuroSense Therapeutics to conduct a study on the effects of PrimeC on neurofilament levels in patients with ALS. The study will be funded by Biogen and use blood samples from 69 PARADIGM patients provided by NeuroSense. The collaboration includes data sharing and joint evaluation of correlations among endpoints. PrimeC is an investigational combination therapeutic comp..
Kura Oncology has announced plans for a $100 million underwritten public offering to fund the development of its three candidate drugs, invest pipeline research and development, and provide general working capital. The company has approximately $406 million in cash, cash equivalents and investments, which it expects will fund current operations until Q4 2025. However, Kura's pre-market share val..
2seventy bio has paused its Phase I CAR T-cell therapy trial for pediatric acute myeloid leukemia after a patient death. The trial was being conducted in partnership with Seattle Children’s, and the company's DARIC technology is used to regulate CAR T-cell responses and enable "on-demand" control of engineered T-cells. The child who died was the first to receive the second dose level of 2seventy..
OraSure Technologies has conducted a study that suggests self-sampling with its Colli-Pee® device is a cost-effective alternative to clinician-collected sampling and other self-sampling methods for routine human papillomavirus (HPV) primary cervical cancer screening. The study, published in the biomedical journal “BMJ Open,” indicates that if self-screening led to a 15% increase in women accessi..
Heligenics, a biotech company based in Las Vegas, has developed a first-of-its-kind precision genetic test that can select among drugs to treat breast cancer. The test uses Heligenics' proprietary GigaAssay technology to identify which of the 10,000 potential mutations in a cancer gene would make a patient susceptible to a drug they would want to take and which variants produced resistance to th..
